Latest news

Hide mandatory notifications of trade

Bionor Pharma's re-vaccination study accepted as a poster at the XVIII International AIDS conference

Bionor Pharma's subsidiary, Bionor Immuno AS recently carried out are-vaccination study at Norway's largest hospital, using Vacc-4x, the company'smost advanced HIV-vaccine candidate

(Oslo, Norway, 21 June 2010)


Bionor Pharma's subsidiary, Bionor Immuno AS recently carried out a

re-vaccination study at Norway's largest hospital, using Vacc-4x, the company's

most advanced HIV-vaccine candidate. Twenty six of the forty HIV-patients from

the 2002/03 phase IIa study were followed-up and re-vaccinated during the period

January 2010-June 2010.


The abstract of baseline data from this re-vaccination study will be presented

as poster at the XVIII International AIDS conference, 18-23 July 2010 in Vienna,

under the title: "Long-term proliferative CD4+ and CD8+ T-cell memory detected

7 years after intradermal immunizations against short HIV gag p24-like peptides

targeting dendritic cells."


The International AIDS Conference ( is the largest HIV/AIDS

conference globally. It is held every second year and is an important meeting

place for the international HIV scientific community, pharmaceutical industry,

politicians and media. The Scientific Programme Committee of the conference

selects poster presenters based on a scientific peer- review process. Therefore,

the selection of the abstract from Bionor Pharma is a recognition from the

scientific community of both its news interest and high scientific standards,

even more because Bionor's abstract was a late breaker.


This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)


About Bionor Immuno


Bionor Immuno is an innovative biotech company developing pharmaceutical-grade

peptide vaccines that stimulate cell-mediated immunity using T-cell stimulation.

Bionor Immuno carefully designs synthetic peptides from non-mutating parts of

the virus with improved immunogenicity, resulting in improved efficacy and

safety profiles. HIV is the first disease targeted, with the most advanced

vaccine candidate about to finish clinical phase IIb. However, Bionor Immuno's

platform technology is broadly applicable, and the company has vaccine

candidates also for chronic infections such as Hepatitis C (HCV), Human

Papilloma Virus (HPV) and Influenza. Bionor Immuno is a wholly owned subsidiary

of Bionor Pharma ASA, listed on the Oslo Stock Exchange under the ticker symbol